Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04447404 · ClinicalTrials.gov registry record · Phase 2
DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury
A Phase 2 study, sponsored by Durect.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04447404 is a Phase 2 study that was terminated before completion, run by Durect. The registered enrollment target is 2 participants.
The verdict
NCT04447404, a Phase 2 study, was terminated before completion, sponsored by Durect.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
Interventions
- DRUG Placebo
- DRUG DUR-928
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-09-21 |
| Est. Completion | 2021-03-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04447404
The ClinicalTrials.gov registry entry for NCT04447404 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Durect, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04447404 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04447404 about?
NCT04447404 is a clinical study titled "DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury". Evaluate safety and efficacy of DUR-928 in treatment of acute organ failure in subjects infected with SARS-CoV-2
What is the current status of trial NCT04447404?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-09-21. Estimated completion is 2021-03-04.
What interventions are being tested in trial NCT04447404?
The interventions under investigation include: Placebo (DRUG), DUR-928 (DRUG).
Who is sponsoring clinical trial NCT04447404?
This trial is sponsored by Durect, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.